Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive

PHASE2TerminatedINTERVENTIONAL
Enrollment

297

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

July 31, 2014

Conditions
HIV-1 Infection
Interventions
DRUG

BMS-986001

Capsules, Oral, 100 mg, Once daily, At least 48 weeks

DRUG

BMS-986001

Capsules, Oral, 200 mg, Once daily, At least 48 weeks

DRUG

BMS-986001

Capsules, Oral, 400 mg, Once daily, At least 48 weeks

DRUG

Placebo matching with BMS-986001

Capsules, Oral, 0 mg, Once daily, At least 48 weeks

DRUG

Efavirenz

Tablets, Oral, 600 mg, Once daily, Entire Treatment Phase

DRUG

Lamivudine

Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase

DRUG

Tenofovir

Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase

Trial Locations (51)

1

Local Institution, Cercado

4

Local Institution, Barranco

31

Local Institution, San Martín de Porres

1097

Local Institution, Budapest

1871

Local Institution, Liverpool

2010

Local Institution, Darlinghurst

2013

Local Institution, Soweto

2198

Local Institution, Johannesburg

3000

Local Institution, Dundee

3004

Local Institution, Melbourne

4001

Local Institution, Durban

Local Institution, Durban KZN

7530

Local Institution, Cape Town

7925

Local Institution, Cape Town

9301

Local Institution, Bloemfontein

10011

Local Institution, New York

10330

Local Institution, Bangkok

10400

Local Institution, Bangkok

10461

Jacobi Medical Center, The Bronx

10700

Local Institution, Bangkok

11000

Local Institution, Nontaburi

14215

University At Buffalo, Buffalo

19104

University Of Pennsylvania, Philadelphia

20009

Local Institution, Washingtondc

28040

Local Institution, Madrid

28209

Local Institution, Charlotte

29203

Local Institution, Columbia

30308

Aids Research Consortium Of Atlanta, Atlanta

32803

Orlando Immunology Center, Orlando

33401

Triple O Medical Services, P.A., West Palm Beach

40002

Local Institution, Khon Kaen

46202

Indiana University, Indianapolis

55404

Clinic 42 And International Travel Clinic, Minneapolis

69004

Local Institution, Lyon

75246

North Texas Infectious Disease Consultants, Dallas

76104

Tarrant County Infectious Disease Associates, Fort Worth

77004

Therapeutic Concepts, P.A., Houston

77401

St. Hope Foundation, Bellaire

78705

Central Texas Clinical Research, Austin

95817

Uc Davis Medical Center, Sacramento

8207257

Local Institution, Santiago

8330744

Local Institution, Santiago

C1426EGR

Local Institution, Ciudad de Buenos Aires

V6Z2C7

Local Institution, Vancouver

H2L 4P9

Local Institution, Montreal

H2L 5B1

Local Institution, Montreal

Unknown

Local Institution, Bogota

Local Institution, Iquitos

06470

Local Institution, Mexico City

08916

Local Institution, Badalona

08036

Local Institution, Barcelona

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY